Roche gifts blockbuster cancer drug to Galecto for new clinical partnership trial
Biotech company Galecto has partnered up with Roche, with the latter providing its cancer treatment Tecentriq free of charge for a mid-phase trial testing a combination of the blockbuster drug with one of three Galecto candidates. The deal is a significant cost saver for the Danish biotech company, which doesn't even have to surrender commercial rights for the potential combination treatment.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN
The Danish-Swedish firm Galecto Biotech, which is spearheded by President and CEO Hans Schambye, has entered into a partnership with one of the giants of the pharmaceutical industry.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Galecto begins third phase II trial
For subscribers
